Sarecycline

Caitlin Soto, PharmD, BCIDP, Fidelia Bernice, Pharm.D.

INDICATIONS

FDA

  • Treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients ≥ 9 years old.
    • Efficacy beyond 12 weeks and safety beyond 12 months have not been established.

NON-FDA APPROVED USES

  • Papulopustular rosacea[5]
  • Periorificial dermatitis[3]

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: November 8, 2026